The calcium channel TRPV6 is a novel regulator of RANKL‐induced osteoclastic differentiation and bone absorption activity through the IGF–PI3K–AKT pathway

Abstract

Objectives Calcium ion signals are important for osteoclast differentiation. Transient receptor potential vanilloid 6 (TRPV6) is a regulator of bone homeostasis. However, it was unclear whether TRPV6 was involved in osteoclast formation. Therefore, the aim of this study was to evaluate the role of TPRV6 in bone metabolism and to clarify its regulatory role in osteoclasts at the cellular level. Materials and methods Bone structure and histological changes in Trpv6 knockout mice were examined using micro‐computed tomography and histological analyses. To investigate the effects of Trpv6 on osteoclast function, we silenced or overexpressed Trpv6 in osteoclasts via lentivirus transfection, respectively. Osteoclast differentiation and bone resorption viability were measured by tartrate‐resistant acid phosphatase (TRAP) staining and pit formation assays. The expression of osteoclast marker genes, including cathepsin k, DC‐STAMP, Atp6v0d2 and TRAP, was measured by qRT‐PCR. Cell immunofluorescence and Western blotting were applied to explore the mechanisms by which the IGF‐PI3K‐AKT pathway was involved in the regulation of osteoclast formation and bone resorption by Trpv6. Results We found that knockout of Trpv6 induced osteoporosis and enhanced bone resorption in mice, but did not affect bone formation. Further studies showed that Trpv6, which was distributed on the cell membrane of osteoclasts, acted as a negative regulator for osteoclast differentiation and function. Mechanistically, Trpv6 suppressed osteoclastogenesis by decreasing the ratios of phosphoprotein/total protein in the IGF–PI3K–AKT signalling pathway. Blocking of the IGF–PI3K–AKT pathway significantly alleviated the inhibitory effect of Trpv6 on osteoclasts formation. Conclusions Our study confirmed the important role of Trpv6 in bone metabolism and clarified its regulatory role in osteoclasts at the cellular level. Taken together, this study may inspire a new strategy for the treatment of osteoporosis.

The mechanism of Epimedin B in treating osteoporosis as revealed by RNA sequencing‐based analysis

“…Extensive studies have indicated that RANKL induces oscillatory changes in intracellular Ca 2+ concentrations and activates nuclear factor of activated T cells c1 (NFATc1), resulting in osteoclast-specific gene transcription to induce osteoclast differentiation. 34 GO created evidencesupported annotations to help predict the biological roles of genes regulated by Epimedin B by classifying them using ontologies in a computable collaborative way and the results suggested that the genes affected by Epimedin B involved in biological roles related to osteoporosis.…”

Network Pharmacology-Based Investigation on the Anti-Osteoporosis Mechanism of Astragaloside IV

“…33 Studies have shown that growth factors such as insulin and insulin-like growth factor (IGF) can activate the PI3K/Akt signaling pathway, thereby affecting the formation, differentiation and function of osteoblasts and osteoclasts, and play a role in regulating bone mass and bone strength. 34 Akt, also known as protein kinase B (PKB), is a serine/threonine specific protein kinase. Akt1 can phosphorylate FoxO3a and prevent it from accumulating to the nucleus, which can transactivate the destruction of the pro-apoptotic molecule (Bim) in osteoblasts of its downstream target gene, thereby inhibiting osteogenic apoptosis.…”

Roles of calcium signaling in cancer metastasis to bone

“…The TRP cation channels also make a contribution to osteoclast differentiation, for example, TRPC1, TRPV4, and TRPV5 are essential for the regulation of osteoclastogenesis [ 56 – 58 ]. In a recent study, osteoporosis and enhanced bone absorption were found in TRPV6 knockout mice [ 59 ]. TRPV6 channels decreased the ratios of phosphorylation in the PI3K-AKT pathway which mediates the regulation of osteoclast formation and bone resorption ( Figure 2e ) [ 59 ].…”